Analyzing the Price-to-Earnings Ratio of Rocket Pharmaceuticals Inc (RCKT)

PARA

The price-to-earnings ratio for Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is above average at N/Ax. The 36-month beta value for RCKT is also noteworthy at 0.67. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 2 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”

The average price estimated by analysts for RCKT is N/A, which is -$5259990.97 below than the current price. The public float for RCKT is 99.77M, and at present, short sellers hold a 14.07% of that float. The average trading volume of RCKT on July 01, 2025 was 5.26M shares.

RCKT) stock’s latest price update

The stock price of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has jumped by 6.09 compared to previous close of 2.45. Despite this, the company has seen a fall of -6.17% in its stock price over the last five trading days. globenewswire.com reported 2025-07-01 that NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

RCKT’s Market Performance

RCKT’s stock has fallen by -6.17% in the past week, with a monthly rise of 3.55% and a quarterly drop of -61.03%. The volatility ratio for the week is 6.60% while the volatility levels for the last 30 days are 8.92% for Rocket Pharmaceuticals Inc The simple moving average for the last 20 days is -7.63% for RCKT’s stock, with a simple moving average of -75.55% for the last 200 days.

Analysts’ Opinion of RCKT

Many brokerage firms have already submitted their reports for RCKT stocks, with Evercore ISI repeating the rating for RCKT by listing it as a “In-line.” The predicted price for RCKT in the upcoming period, according to Evercore ISI is $5 based on the research report published on May 30, 2025 of the current year 2025.

Morgan Stanley, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $7. The rating they have provided for RCKT stocks is “Equal-Weight” according to the report published on May 28th, 2025.

Leerink Partners gave a rating of “Market Perform” to RCKT, setting the target price at $8 in the report published on May 28th of the current year.

RCKT Trading at -46.60% from the 50-Day Moving Average

After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.37% of loss for the given period.

Volatility was left at 8.92%, however, over the last 30 days, the volatility rate increased by 6.60%, as shares sank -9.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.27% lower at present.

During the last 5 trading sessions, RCKT fell by -9.21%, which changed the moving average for the period of 200-days by -86.78% in comparison to the 20-day moving average, which settled at $2.81. In addition, Rocket Pharmaceuticals Inc saw -87.87% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at RCKT starting from Militello John, who sale 357 shares at the price of $6.45 back on May 20 ’25. After this action, Militello John now owns 64,027 shares of Rocket Pharmaceuticals Inc, valued at $2,301 using the latest closing price.

Schwartz Jonathan David, the of Rocket Pharmaceuticals Inc, sale 801 shares at $6.45 during a trade that took place back on May 20 ’25, which means that Schwartz Jonathan David is holding 235,255 shares at $5,163 based on the most recent closing price.

Stock Fundamentals for RCKT

Current profitability levels for the company are sitting at:

  • N/A for the present operating margin
  • N/A for the gross margin

The net margin for Rocket Pharmaceuticals Inc stands at N/A. The total capital return value is set at -0.62. Equity return is now at value -60.45, with -53.17 for asset returns.

Based on Rocket Pharmaceuticals Inc (RCKT), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -8.23. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -143.2.

Currently, EBITDA for the company is -273.2 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of N/A. The receivables turnover for the company is N/Afor trailing twelve months and the total asset turnover is N/A. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.19.

Conclusion

In summary, Rocket Pharmaceuticals Inc (RCKT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Most Popular

Related Posts

favicon-nh
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.